12th Annual:
Latest Advancements and Data in Immuno-Oncology
Hear directly from science and business stakeholders on the latest data impacting IO to fight a wider range of cancers.
IO360° Delivers 4 Key Benefits
1. Delivering a 360° IO Community to Network and Form Collaborations
Build faster and more impactful collaborations with researchers, clinicians, biopharma leaders, investors and policymakers to advance cancer treatments
2. The Latest Data Driving Broader Impact
Hear directly from KOLs on the latest data to help advance and improve outcomes for more patients across a wider range of cancers
3. 360° Future-Focused Agenda
Stay ahead of the curve through 100+ multi-dimensional talks covering preclinical research, translational science, clinical development, operational strategies, cell therapy and business advancements
4. 10+ Hours of Networking Opportunities
Meet with key stakeholders in biopharma, academia, investors and regulatory through 1:1 meetings and scheduled functions
2026 VIP All-Star Line Up
Checkpoints and Beyond: Next Era of IO
Dr Jedd Wolchok
Weill Cornell Medicine
Targeting Myeloid Cells
Dr Miriam Merad, MD, PhD
Mount Sinai School of Medicine
Redefining Cancer Immunity
Dr Ira Mellman, PhD
Parker Institute for Cancer Immunotherapy (PICI)
Strategic Innovations & Industry Trends
Dr Andrew Baum
Pfizer
Translational Science & Clinical Development Trailblazers
Dr Charles Drake
J&J Innovative Medicine
Dr Sarah Warren
Kite Pharma, a Gilead Company
Dr Susan Bates
Columbia University Medical Center
Dr Christine Ward
Moderna
Dr Sabah Öney
Dispatch Bio
Dr Amal Melhem-Bertrandt
Jazz Pharmaceuticals
Investment and Business Development Pioneers
Rajiv Kaul
Fidelity Investments
David Stadinski
Piper Sandler
Dr I-hung Shih
Eventide Asset Management
Dr Markus Werner
Novartis
Kalli Dircks
Morgan Stanley
Dr Reni Benjamin
Citizens Capital Markets and Advisory
Innovators in IO Biotech
Dr Ramy Ibrahim
Georgiamune
Dr Ying Gong
GV20 Therapeutics
Dr Adrian Bot
Capstan Therapeutics
Dr Claire Thuning-Roberson
AbBC Therapies
Dr Zdravka Medarova
TransCode Therapeutics
2026 Key Topics
Biomarkers/Assay Development
Business and Investing Aspects
Discovery/Preclinical
Autoimmune Disease & IO
ADCs & IO
IO Combinations
Translational Science
Imaging Advancements
Cell Therapy
Neoadjuvant/Adjuvant
Clinical Developments
And More
Networking and Business Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search attendee profiles
• Send private message to attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
.png)
.png)
.png)
Who Attends
.png)
Companies Attending:
• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope
• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley
• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
Dr Kristen Hege Looks Back at Lessons Learned from a Career in CAR-T Therapy
Taking Lessons from the Last Decade of IO to Develop the Next Wave of Therapeutics
Dr Roy Baynes on Strategy Development for Keytruda
2025 Sponsors
